Respiratory Infections Market Size & Share, by Drug Class (Non-Steroidal Anti-Inflammatory Medication, Antihistamines, Cough Suppressants, Expectorants, Decongestants); Form (Tablets & Lonzenges, Powders, Sprays, Ointments); Route of Administration (Oral, Topical, Nasal); Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Drug Store) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 5753
  • Published Date: Feb 28, 2024
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2024-2036

Respiratory Infections Market size is expected to reach USD 990 Billion by the end of 2036, growing at a CAGR of 2% during the forecast period i.e., 2024-2036. In the year 2023, the industry size of respiratory infection was over USD 200 Billion. There is a large selection of medicinal goods and therapy choices that are portable. This has led to the market for over-the-counter medications (OTC) holding more than 80% of all upper respiratory tract pharmaceuticals. The market for respiratory infections is expected to be driven by the extensive availability of medications and their relatively inexpensive cost.

One of the main reasons for hospital visits by outpatient patients is upper respiratory infection. Upper respiratory tract infection occurs in a higher part of the respiratory tract. Nasal passages, sinuses, pharynx, and trachea are the specific areas that are most affected by the infection. The respiratory infections drugs are one of the common treatment available in the market.


Respiratory Infections Market
Get more information on this report: Request Free Sample PDF

Respiratory Infections Sector: Growth Drivers and Challenges

Growth Drivers

  • Growing Product Launches and R&D - New manufacturers are expected to be attracted to the market for nonprescription upper respiratory infections by a lenient regulatory regime in the US Food and Drug Administration on OTC medicinal products. Thus, product launches, research, and developments from key manufacturers in the respiratory infections market are evolving into product segments. Example: The launch of Otrivin nasal spray by Novartis has led to similar product launches by other key players in the market.
  • High Incidence of Common Cold - The essentially high rate of the common cold is one of the prime conditions of upper respiratory infections, successively expected to be one of the prime variables for the non-prescription upper respiratory infections showcase development. Sudden and diligent climate changes coupled with expanding seriousness of air pollution is expected to be one the prime figure expanding the rate of upper respiratory disease. 

Challenges

  • Strict Regulatory Standards - The growth of the market in the forecast period will be hampered by a stringent regulatory framework, together with unfavourable reimbursement policies and an inadequate level of awareness for patients.
  • Cost and Time complexities associated are expected to hamper the market growth in the upcoming period
  • Lack of Effective Vaccines for Some respiratory viruses are estimated to pose limitation on the market growth in the forecast period.

Respiratory Infections Market: Key Insights

Base Year

2023

Forecast Year

2024-2036

CAGR

~2%

Base Year Market Size (2023)

~USD 200 billion

Forecast Year Market Size (2036)

~USD 990 billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Respiratory Infections Segmentation

Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Drug Store)

In terms of distribution channel, the hospital segment in the respiratory infections market is set to hold the largest share of 40% by the end of 2036. The purchase of medicines needed to treat the upper respiratory tract is carried out by hospital pharmacies in close cooperation with suppliers and pharmaceutical companies. They're stored in pharmaceutical warehouses after that. The inventory management systems help to keep stock levels under control and ensure that an adequate supply of medicinal products for patients with breathing difficulties is available. In addition, hospital pharmacies frequently teach patients how to use their respiratory medicines properly. Better patient compliance and more efficient distribution of medicines are a result of this education. These factors will contribute to the growth of hospital pharmacies, which are expected to be a driving factor for market development in the forecast period.

Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Drug Store)

In terms of end use, the drug store segment in the respiratory infections market is anticipated to account for a significant share by the end of the forecast period. The mounting competition within the nonprescription upper respiratory infections advertise is profoundly unstable and the nearness of major worldwide key players has revolutionized the research and improvement within the fabricating industry. The penetration of medicate dispersion channel is broadly established within the supply of respiratory infections drugs, expeditiously satisfying the request from medicate stores 

Our in-depth analysis of the global market includes the following segments:

          Drug Class

  • Non-Steroidal Anti-Inflammatory Medication
  • Antihistamines
  • Cough Suppressants
  •  Expectorants
  • Decongestants

           Form

  • Tablets & Lonzenges
  •  Powders
  • Sprays
  • Ointments

           Route of Administration

  • Oral
  • Topical
  • Nasal

           Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Drug Store

            Form

  • Tablets & Lonzenges
  •  Powders
  • Sprays
  • Ointments

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Respiratory Infection Industry - Regional Synopsis

North American Market Forecasts

The respiratory infections market in the North America region is set to hold a CAGR of 35% by the end of 2036. The development in the region can be attributed to the developing burden of respiratory maladies and a higher predominance of smoking. According to the Centre for Disease Control and Prevention, in 2018, the predominance of Asthma was found to be around 6.2% in males and 9.1% in females within the United States. Moreover, around 6.2% of individuals were detailed with chronic obstructive pneumonic diseases within the United States. Consequently, these variables are expected to drive the development of the showcase within the estimated period. The selection of quick diagnostics tests for quicker determination of respiratory irresistible illnesses is another key factor expected to expand the respiratory irresistible infection diagnostics advertise within the locale. 

APAC Market Statistics

The respiratory infections market in the Asia Pacific region is set to grow significantly during the projected period. The growth of this market can be primarily ascribed on the back of the increasing practice of self-medication in the region. There is a growing awareness of respiratory diseases in the Asia Pacific region and this is leading to increased diagnosis and treatment rates. Many governments in the region are launching campaigns to raise awareness of respiratory diseases and encourage people to seek treatment. The healthcare infrastructure in many countries in the region is enhancing, making it easier for people to access diagnosis and treatment for regulatory diseases.

Research Nester
Respiratory Infections Market Size
Get more information on this report: Request Free Sample PDF

Companies Dominating the Respiratory Infection Landscape

top-features-companies
    • Pfizer Inc.
    • Company Overview
    • Business Strategy
    • Key Product Offerings
    • Financial Performance
    • Key Performance Indicators
    • Risk Analysis
    • Recent Development
    • Regional Presence
    • SWOT Analysis
    • Alcon, Inc.
    • Collegium Pharmaceutical Inc.
    • Merck & Co. Inc.
    • GlaxoSmithKline plc
    • Verona Pharma Plc
    • Teva Pharmaceuticals
    • Sandoz Inc.
    • Hospira Inc.
    • Novacyt Group

In-the-news

In The News

  • Novacyt, an international specialist in clinical diagnostics, announces the launch in August 2020 of its CEMark approved PCR respiratory test panel, Winterplex. The test panel is intended for use on any open PCR platform and, in particular, the Company's rapidly transportable Q32 device.
  • Pfizer Inc. reported that the U.S. Food and Drug Administration has endorsed ABRYSVO™ , the company's bivalent RSV prefusion F immunization, for the anticipation of LRTD and serious LRTD caused by RSV in newborn children from birth up to six months of age by dynamic immunization of pregnant people at 32 through 36 weeks gestational age. ABRYSVO is unadjuvanted and composed of two preF proteins chosen to optimize assurance against RSV A and B strains and was watched to be secure and viable. The FDA's choice is based on the information from the significant Stage 3 clinical trial MATISSE , a randomized, double-blinded, placebo-controlled Stage 3 consider outlined to assess the adequacy, security, and immunogenicity of the antibody against LRTD and extreme LRTD due to RSV in newborn children born to solid people immunized amid pregnancy.

Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 5753
  • Published Date: Feb 28, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The growing prevalence of respiratory disease and growing incidence of common cold are some of the major factors anticipated to drive the growth of the respiratory infections market.

The market is anticipated to attain a CAGR of ~2% over the forecast period, i.e., 2024-2036.

The major players in the market are of GlaxoSmithKline plc, Verona Pharma Plc, Teva Pharmaceuticals, Sandoz Inc., Hospira Inc., Novacyt Group, and others.

The hospital segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in North America is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Respiratory Infections Market Report Scope
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying